Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation.

Medicine - 7 Nov 2025

Liu Na, Xu Shu, Xie Yuwen, Xu Ting, Fang Hehui, Wang Xiaoyue, Yang Liangfeng, Fang Shencun

Abstract excerpt

Elderly non-small cell lung cancer (NSCLC) patients do not always benefit from standard treatments due to impaired organ function and/or multiple comorbidities. Our study aimed to determine the efficacy and safety of aumolertinib as a first-line therapy in NSCLC patients aged ≥65 and <65 years in clinical practice.We enrolled 100 patients with stage IIA-IVB epidermal growth factor receptor-mutant NSCLC who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Age Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Indoles

Share to Progression-Free Survival

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 41204558
DOI: 10.1097/MD.0000000000045702
PMCID: PMC12599707

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation.PMID 41204558Read ↗

Real-world study of first-line therapy with aumolertinib for elderly patients with non‑small cell lung cancer harboring EGFR mutationSemantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.Semantic proximity Read ↗

Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations.Semantic proximity Read ↗

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.Semantic proximity Read ↗

Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.Semantic proximity Read ↗

The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.Semantic proximity Read ↗

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).Semantic proximity Read ↗

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.Semantic proximity Read ↗

Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.Semantic proximity Read ↗

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.Semantic proximity Read ↗

Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).Semantic proximity Read ↗

Efficacy and safety of anlotinib plus EGFR-TKI for advanced non-small cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.